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Asthma and allergic diseases can start in childhood and persist throughout life, but could also be
manifested later, at any time for still misunderstood reasons. They are major chronic multifactorial
respiratory diseases, for which prevention, early diagnosis and treatment is recognized as a priority for
the Europe's public health policy and the United Nations. Given that allergy triggers (including infections,
rapid urbanization leading to loss in biodiversity, pollution and climate changes) are not expected to
change in a foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize
preventive and treatment strategies. Currently there are good treatments for asthma, several risk factors
are known (e.g., allergies, rhinitis, tobacco smoke) and tools to control the disease have been developed.
However, we are still uncertain how to prevent patients from developing asthma and allergic diseases. In
this paper, we list the positive and negative experiences in this field as well as analyze the missing links
in the process. This critical analysis will be the basis of setting-up an effective program for prevention
and making, a process labeled as “implementation gaps”.
© 2017 Elsevier Ltd. All rights reserved.Contents
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no).1. What do we still have to learn regarding asthma control
and prevention?
Asthma, associated with respiratory allergies, is recognized by
the World Health Organization (WHO) [1] and the United Nations
L.K. Tanno et al. / Respiratory Medicine 130 (2017) 13e1914[2] as the most common chronic inflammatory disease character-
ized by paroxystic symptomatic periods [3,4]. It affects 5e7% of
adults and 10e12% of children. In contrast to some countries in
which frequency of asthma has been stabilized, morbidity statistics
are still raising in others. In France, for example, asthma prevalence
increased from 8.2% in 1998 to 10.2% in 2006 [5]. Though asthma
mortality rates are higher in lower and lower-middle income
countries, it has been accepted as a major public health problem in
all countries.
Several facts related to the evolution of our environment, would
be responsible for the increase or the non-decrease of asthma
including increased potentiating factors such as (i) indoor pollution
and chemicals (cleaning, wood combustion, fume, fine particles),
and biological (mites, mold, animals); (ii) climate changes and
external pollution, in particular, the fine particles emitted by diesel
engines and ozone; the smoking habit leads to respiratory and non
respiratory diseases (cancers, atherosclerosis, chronic obstructive
pulmonary disease, for example), but is also related with the
development of asthma and allergies in newborns from smoking
pregnant women; (iii) rapid urbanization and its negative conse-
quence leading to changes in biodiversity [6] and loss of protective
factors, which is the basis of the popular “hygiene hypothesis”. This
hypothesis is based on the population observation over the past 30
years in which there was an inverse relationship between the
prevalence of infectious diseases and the frequency of allergic and
autoimmune diseases. The immunological explanation comes from
farmer-based studies. Thus, exposure in the youngest age to en-
dotoxins through the inhaled air (from the wall of bacteria living in
the digestive tract of farm animals) could protect against the
development of allergenic sensitization and respiratory allergies.
Many international initiatives have been launched to prevent
and decrease morbidity and mortality of these conditions, which
are considered a global public health problem [3,7]. However, the
WHO's international classification and coding systems such as the
International Classification of Diseases (ICD) have grouped them
under topographic distribution, regardless of the underlying
mechanisms and triggers. This has led to the framework of ICD to be
deficient in capturing the concepts currently in use for allergic and
hypersensitivity conditions, in particular for allergic and hyper-
sensitivity conditions of the respiratory tract. As a result, the lack of
accurate morbidity and mortality epidemiological data impacts
directly on the healthcare prevention planning and resource allo-
cation, quality patient management and public health policies.
The public health's core mission is prevention of injury or dis-
ease and there are several potential strategic interventions. Most
population interventions have historically focused on primary and
secondary prevention measures, but all health professionals
worldwide are most familiar with asthma tertiary prevention ac-
tions since they are addressed to existing disorders and focused on
their accurate diagnosis and control in order to avoid new exacer-
bations [1].
Though the epidemiological and genetic studies have been
looking for many different risk factors for asthma [8], they have
failing to reach objective makers to substantiate preventive mea-
sures. These studies have supported some broad hypotheses and
proposed some effective tips. In families where there is a history of
asthma and allergies, we should indeed try to prevent asthma in
young children by simple measures, such as avoiding smoke during
pregnancy or in the presence of infants and young children,
preferring breastfeeding for the first 3 months and provide early
diversification from the age of four months.
Although not fully demonstrated, some measures have been
recommended to prevent allergy. Removing allergens from the
indoor environment (dust mites, pets, mold) showed to be inef-
fective as primary prevention, but it is effective in secondaryprevention, when the eviction is completed and prolonged.
Delayed diagnosis of allergies and asthma, primarily linked to
the lack of knowledge of asthma-like symptoms or misinterpreta-
tion of laboratory tests related to allergies, precludes the develop-
ment of early prevention. Rhinitis, which includes hay fever
(allergic rhinitis to grass pollen) and allergic rhinitis due to mites
are risk factors for the development of asthma later in life and of
uncontrolled established asthma [7]. Based on it, some national
screening and prevention campaigns have been set up. The best
example is from Finland [9]. After 10 years of intensive work of
training health professionals, providing information for the popu-
lation, implementing of treatment guidelines, the cost of asthma for
the Finnish health has fallen considerably and the amounts origi-
nally invested appear to have been fully repaid. However, the
incidence of asthma has not decreased during that period, which
means that the causes of the disease have not been affected and/or
the methodology applied to reach precise asthma epidemiological
data was not optimal. The same country, while others have since
copied, bounced and implemented a national program of allergy
prevention, thinking to tackle one of the causes of asthma [10]. The
question that therefore arises is indeed the subject of this article:
can we really prevent asthma? What are the obstacles? Can we
overcome them? Should other countries engage in such a process?
2. Can we really control asthma?
The goal of treatment of asthma is to control the disease with
minimal drug and to reach an appropriate quality of life for pa-
tients. In France, it has been observed that uncontrolled asthma
affects nearly one child in two (44.2%) [11] and three in five adults
(62%) [5].
Asthma control has two main goals: (I) clinical control and (II)
limitation or reduction of future risk of adverse outcomes. Actions
to reach both objectives have to be taken concurrently for a suc-
cessful control. In the case of children, the disease control should
lead to the absence of symptoms in the performance of a normal life
without limitation (at school, in recreation, sport), standardization
of lung function, allowing a good development height and weight,
and of course to prevent mortality caused by the disease, which
unfortunately still exists (with 10 deaths from asthma in 0e14 of a
total of just under 1000 asthma deaths in France in 2010) [12].
Similarly, older people with asthma are under-diagnosed and
under-treated, increasing mortality statistics [13].
Preventive measures should be able to change the natural his-
tory of the disorder, preventing asthma development and/or evo-
lution providing its control. Asthma attacks start in early ages and
are only the visible part of the iceberg. Childhood asthma is a
chronic disease that comes in many forms (known clinical pheno-
types) some strongly linked to allergies and others not [14e16].
Recently several studies have explored the treatment of intermit-
tent and persistent forms of the disease. Generally, inhaled short-
acting beta2-agonists acting in minutes are pointed as the treat-
ment of choice in crises by numerous recommendations [17e20]. In
addition, the daily use of inhaled corticosteroids (ICS), which con-
stitutes the reference indication in overall control of the long-term
asthma, has shown effective in reducing asthma exacerbations and
rescue medications use [21]. The occasional use of several treat-
ments in intermittent forms especially during infectious episodes
was investigated in seven recent studies. In the case of ICS, there
was no [22e24] or low [25,26] positive effects in terms of reducing
the number of exacerbations; the beneficial effect was modest for
leukotriene receptor antagonists (LTRA) [27,28]. The lack of written
asthma action plan and education of parents and teenagers is also a
paramount difficulty of achieving asthma control, notably due to
the “no symptom, no asthma” belief and the lack of knowledge
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From all the existing recommendations [17e20], taking daily ICS
is effective in controlling persistent forms of asthma. The benefits of
ICS are to be balancedwith decreased of children growthwith short
terms (1.1 cm on average in the first year, potentially reversible the
years after), dependable on the dose and on the ICS formulation
[29].
A systematic review of the literature [30] of the last 16 years has
shown the advantages of using the combination of ICS þ long-ac-
tion b2-agonists (LABA) compared to ICS alone in children and
adolescents with uncontrolled persistent asthma, from prospective
randomized clinical studies (9 studies), 1641 children with asthma,
allowing to compare ICS þ LABA vs. double dose of ICS (7 studies)
and ICS vs. higher doses (2 studies). The ICS þ LABA association
significantly improved morning and evening peak expiratory flow
(PEF) and was associated with reduced use of rescue medication.
Compared with high doses of ICS, the ICS þ LABA combination also
reduced the risk of asthma exacerbations, and the ICS þ LABA
combination was not affecting the growth of the children.
Results are contradictory regarding the LTRA in asthma. Two
previous studies showed the decrease of bronchial hyperreactivity
and exhaled nitric oxide fraction (bronchial eosinophilic inflam-
mation marker) [31], asthma symptoms and doctor visits [32], but
no difference was observed when LTRAs were associated with the
usual treatment in another study [33].
The choice of the optimal system for the administration of
inhaled drugs is also crucial in the management of asthma in pe-
diatric patients. The inhaled drugs currently remain the most
effective forms of treatment administration for respiratory disor-
ders. The optimal devices should allow bringing a significant
amount of drugs directly to the bronchi. Two inhalation systems
can be used in children: inhalation chambers and nebulization. The
spacer accessory intended to be fixed on the mouthpiece of the
metered dose inhalers to facilitate taking the drug by eliminating
the hand-mouth coordination function. The use of a spacer is part
of the international recommendations for mild to moderate exac-
erbations [17,18]. However, the use of chambers brings up some
questions in children. To date, there is no strong evidence sug-
gesting major differences in efficacy between the inhalation sys-
tems, each system having its advantages and limitations [34]. If
unsuccessful by using inhalation chamber, nebulization, especially
with a pneumatic nebulizer should be discussed [35,36].
The non-observance of the drugs used for asthma in children
and adolescents is alarming [37,38]. The adherence to the treat-
ment of children depends on the family, the health care system and
the child health status. Young children are completely dependent of
their parents while teenagers take in, but at a period of life often
associated with experimentation with risky behaviors [37].
Finally, due to lack of appropriate data, one wonders about the
possibility of treating differently the various asthma phenotypes,
particularly the non-allergic asthma in children, the efficacy of
long-term treatments, the dose-response relationship and the
aerosol deposition in small children. Further investigation is
needed to fill these knowledge gaps and optimal control of asthma.
3. Which lessons to learn from the prevention studies?
From the public health perspective, efforts taken in collabora-
tion with WHO ICD leadership and six allergy international acad-
emies to have an improved classification of allergic and
hypersensitivity conditions in current ICD-11 revision [39,40],
resulted in the construction of a pioneer section entitled “Allergic
and hypersensitivity conditions”, in which asthma is one of the
main sub-headings of the “Allergic or hypersensitivity disorders
involving the respiratory tract” section [39,41e48] (Fig. 1). Theconstruction of the new section detailing asthma means that the
latter both allergic and non-allergic asthmawill now be recognized
as clinical conditions requiring specific documentation and man-
agement, such as the indication of allergen immunotherapy or bi-
ologicals (e.g., Omalizumab) for allergic asthma.
Preventive measures must be effective for individuals and reli-
able and financially acceptable to the community. Primary pre-
vention aims to reduce the incidence of the disease by identifying
individuals or populations at risk and reducing exposure to potential
risk factors. In other words, primary prevention is applied to
change the natural history of the disorder. While secondary pre-
vention intends to avoid the development of allergic diseases in
sensitized subjects and tertiary prevention is for sick patients and
the consequences of the disease so as to reduce the burden for the
individuals and for the society [49]. In general, optimal public
health strategies are focused on primary and secondary prevention.
However, in practice, most of the actions to prevent asthma are
tertiary prevention efforts.
Interventional epidemiology evaluates preventive actions un-
dertaken with a set of methodological specifications [50]. The
evaluation of the success of a prevention program is measured by
feasibility criteria, outcomes and costs. The comparison of groups
established by sorting out (randomized intervention trials) repre-
sents the best methodological solution for measuring the effec-
tiveness of such actions, but is not always ethically possible. We can
then make use of observational studies including registries and
cohorts of patients. When the effectiveness of the proposed mea-
sures has been demonstrated, it is necessary to assess the actual
feasibility of these actions at the level of a greater population. The
results obtained from the research program shall be tested and
adapted to the existing, far less controllable in routine than in
research.
In asthma, very few prevention programs have been a break-
through success [8]. Eviction of respiratory allergens, pharmaco-
logical treatment, allergen immunotherapy, diets, pre/pro/
symbiotic education campaign among others are discussed. It has
been shown that not only the eviction measures proposed to pa-
tients allergic to mites cause a significant decrease in allergic
exposure, but there is a correlation between the reduction in
allergen load and clinical improvement [51]. However, to be effi-
cacious these measures must be early, complete (that is to say, not
limited to a single allergen or a single irritant) and prolonged and
should not be extended for primary prevention of sensitization to
inhalant allergens [51]. Indeed, no study has been shown that
primary prevention of allergens prevents the onset of new sensi-
tizations (except as regards occupational latex allergy) [52], as
opposed to recent prevention trials in peanut allergy [53]. Studies
with pre/pro/symbiotic show no prevention of asthma, at most
they are able to delay eczema [54]. The therapeutic management
mainly includes three components (drugs, allergen immuno-
therapy, education), which are implemented in combination or in
steps, depending on the control of symptoms. A century after the
first allergen immunotherapy trial, it remains the only treatment
that can modify the course of the allergic disease [55]. However,
prevention studies (of asthma in rhinitis patients) are of poor
quality methodology [56] and better studies need to be in place,
particularly with the new allergen immunotherapy products.
The Finnish plan for asthma (FAS-P: 1994e2004), extended to
seven countries (Brazil, Chile, China, Hong Kong, Ireland, Japan,
Poland, Singapore), incorporating several strategies was more
effective, has shown a cost-effectiveness reduction of asthma but
without reducing its incidence [9]. This program, uncontrolled, had
clearly stated objectives of promoting early diagnosis and treat-
ment (by ICS) of asthma (by general practitioners and pediatri-
cians), self-management of asthma and action plans, actions
Fig. 1. The “Allergic or hypersensitivity disorders involving the respiratory tract” subsection scattered into the pioneer ICD-11 “Allergic and hypersensitivity conditions” section.
L.K. Tanno et al. / Respiratory Medicine 130 (2017) 13e1916against active and passive smoking and the promotion of educa-
tional measures. The plan was implemented with the help of doc-
tors, pharmacists and nurses relay during 700 meetings involving
more than 35,000 health professionals. The patient associationwas
involved. The success of this program is probably related to the
relay set up by the 21 district hospitals, 271 regional health centers,
200 doctors, 580 nurses and 695 pharmacists asthma referents
which, once educated, assured themselves other training sessions.
This was facilitated by the Finnish health system, totally centered
around five university hospitals and 21 peripheral hospitals
nationwide and by centralized decisions to completely cover
asthma (which is part of the “Special Refund Categories” covering
10 (groups of) diseases).
The cost of this first program was 0.65M V and regular evalua-
tions were performed. In 10 years, the number of hospitalizations
for asthma per year dropped by half and the number of asthma
deaths has also decreased (123 in 1993 against 85 in 2003). The
number of patients on treatment has almost doubled during this
period. No impact on smoking was observed. The overall cost of
asthma decreased from V 218M (V 1611/year/patient) to V 213.5M
(V 1031/year/patient), thus largely repaying the initial investment,
despite the increased number of asthmatics and of drug con-
sumption (from 44 toV 79M). In the absence of such a program, the
estimated cost would have been V 341.5M, giving an economy of V
128M [57]. But despite this, the prevalence of asthma has continued
to increase during this period showing that the causes of asthma
are not affected by this program.Finland has launched in 2008 an allergy plan with a stated
objective to reduce the incidence and burden to the society of
allergic diseases (FAL-P, 2008e2018) [10]. This program is based on
the success/limits of the previous program [9] and the hygienist
and loss of biodiversity assumptions. Echoing the farmers' envi-
ronment studies [64,65], Finnish authors showed a net decline of
biodiversity in 118 adolescents living in Karelia 100e150 km apart,
some in Eastern Finland and the other in Russia [58]. The plant
biodiversity (3 km around each adolescent) and microbial (on their
skin) were analyzed [6]. Atopic adolescents, more in Finland, were
at the center of a poor background in plant and microbial species
(especially gamma-proteo bacteria).
The FAL-P is based on the rich network of asthma professionals
established for 10 years. It is much more child and allergies-
centered than asthma-centered. It is structured around six main
axes with quantified secondary objectives: prevent asthma symp-
toms, prevent allergic rhinitis and atopic dermatitis (promotion of
the concept of good health of the allergic patient, fight against in-
door pollution), increase tolerance to allergens (including food,
evictions to targeted cases only) improve the diagnosis of allergies
(by allergists), reduce occupational allergies, finance severe al-
lergies treatment (based on the FAS-P, insisting on control of
asthma, rhinitis and atopic dermatitis and the management of
anaphylaxis), and reduce the overall cost of allergies.
Aligned to the Finnish example, the Canadian Towards Excel-
lence in Asthma Management/Vers l’Excellence dans les Soins aux
Personnes Asthmatiques (TEAM/VESPA) program used a
L.K. Tanno et al. / Respiratory Medicine 130 (2017) 13e19 17population-based approach to reduce the asthma-related
morbidity, improve patients' quality of life, and optimize the use
of health system resources to improve asthma treatment and to
encourage patient self-management. For it, the TEAM/VESPA pro-
gram included the development, implementation and evaluation of
innovative care improvement strategies that would affect clinical
management, dissemination and adoption of best practices
through clinical expertise and continuing education, as well as
through reinforcement of patient self-management via education
[59].4. Which are the barriers to asthma prevention?
Knowing that triggers of allergic diseases will persist for the
coming few years, it is essential to develop and strengthen mea-
sures of prevention and treatment of allergies. The fact that we still
do not know precisely why a child becomes allergic and asthmatic
is an obstacle, but the analysis of prevention programs that work
and those that do not work sheds light on the needs, barriers and
missing links to succeed prevention.
From the primary prevention perspective, the better under-
standing of the mechanisms of allergies and asthma is funda-
mental. For this, we have for the past 10 years associated geneticists
to our fundamental research; however the found polymorphisms
have posed more questions than solved the issues, and these
polymorphisms, when they are confirmed, explained at most a
third of asthma [60,61].
Epigeneticists are now associated and in a recent paper three
loci accounted for 13% of IgE variation [62] and we hope that less
than 10 years will be needed to further advance in this complex
area. The increased risk of asthma or atopy associated with the
presence of a particular variant is very low (<1.5) and any newdrug,
no useful prediction, no substantial progress in understanding the
pathophysiology have emerged so far. We may have to rethink the
research strategy in this area; this so-called missing heritability is
observed in the genetic study of several other complex traits and
diseases and could be explained by [63] (i) the existence of many
other variants to discover; (ii) the interaction between multiple
genetic variants; (iii) the presence of structural variants or strong
effects of rare variants (present at less than 0.5% of the population,
so too infrequent to be captured by current screening studies); andFig. 2. The implementation gaps for(iv) gene - environment interactions, particularly in utero and in the
first 3e5 years of life. The first examples of genes - environment
interactions [64,65] related to exposure to microbial endotoxins;
the presence of a variant of the CD14 (endotoxin receptor) 159T
variant CD14 is indeed associated with an increased risk of asthma
and allergies in people heavily exposed (endotoxin in house dust,
animal work, a pet at home since birth, contact with farm animals)
and the variant CD14 -159C in subjects not exposed. The mecha-
nisms by which the environment influences genes belong to the
field of epigenetics. They include all the phenomena of modifying
the gene expression pattern without modifying the nucleotide
sequence (methylation of cytosine to 5-methylcytosine in the DNA
CG dimer, histone methylation at lysine residues, the auto-
activation of the transcription of certain genes, microRNA) and
are transmitted from one generation to another.
Secondary prevention actions in the context of asthma aim to
identify sensitized individuals in order to prevent the development
of allergic disorders. Although validated scientific data are lacking
to support the screening the whole population for sensitization, it
might be appropriate to do so in individuals with known risk fac-
tors. An example of secondary prevention to avoid development of
asthma is the hygiene hypothesis. The competitive duality of atopy
and certain infections goes beyond the scope of the hygiene hy-
pothesis according to which being born in a large family, being in
kindergarten before the age of six months, being raised on a farm
increase the risk of exposure to respiratory infections in early
childhood for the former and decrease the risk of allergen sensiti-
zations and asthma. The frequent contacts with animal lipopoly-
saccharides present in their excrements prevent atopy, allergic
rhinitis and (sometimes) asthma. So our Western lifestyle highly
urbanized, would result in the decline of biodiversity in turn pro-
moting the emergence of chronic diseases such as asthma, allergies,
but also diabetes, obesity, cardiovascular diseases and cancers. The
recent examples of the changes of the microbiota (skin, digestive or
respiratory) on and around allergic teenagers [6,54] open new
horizons. Thus, associating other scientists (microbiologists here)
to our thinking is very important. Further studies are required to
identify risk factors for asthma exacerbations (role of viruses, al-
lergens, behavioral disorders, stress) [66, 67] and to identify the
best window (age) is fundamental to intervene.
Tertiary prevention programs have to have both short-termasthma prevention and control.
L.K. Tanno et al. / Respiratory Medicine 130 (2017) 13e1918objectives on morbidity (emergency and unscheduled visits, hos-
pitalizations, mortality, other morbidity) and longer terms objec-
tives of reducing the incidence of the disease. They have to involve a
plan (Fig. 2) addressing both allergies and asthma. New anti-
inflammatory therapies, immunomodulators (with promotion of
allergen immunotherapy), new combination therapies, combined
with an extensive educational program may allow to act on the
control of the diseases and the prevention of severe forms.
Although clinical research has been developing substantially over
the last years to ensure efficacy and safety of drugs, challenging is
reaching the best therapies for each patient or group of patients.
Considering asthma as a heterogeneous disease with different
phenotypes and endotypes, it is expected for the forthcoming years
developments in the personalized medicine and the worldwide
availability of these pharmacological formulations in affordable
prices.
The Finnish FAS-P/FAL-P and the Canadianmodels fulfill many of
these gaps and should certainly be followed. The implementation
of a specific section dealing with allergic and hypersensitivity dis-
orders of the respiratory tract will allow reaching refined and
comparable morbidity and mortality data in the forthcoming years.
It is a relevant academic, political and economic move, which will
support new perspectives for a better diagnosis and management
of asthmatic patients.Funding
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